Clindamycin palmitate and potassium phenoxymethyl penicillin were evaluated in 103 children with upper respiratory illnesses and pharyngeal group A streptococci, from November 1970 to July 1971. The children were assigned randomly by weight to one of the antibiotic regimens given orally for 10 days. Clindamycin palmitate and potassium phenoxymethyl penicillin dosages were 75 and 125 mg, respectively, in 5 ml tid for children weighing less than 25 kg, and 150 and 250 mg, respectively, in 10 ml bid for children weighing 25 kg or more. Recurrences of the original streptococcal group A, M, and T types within 3 weeks after the end of treatment were classified as failures. The failure rates were: clindamycin palmitate, 10% (5 of 52), and potassium phenoxymethyl penicillin, 18% (9 of 51). Possible drug-related rashes were observed in 8 of 52 clindamycin palmitate-treated patients. The geometric mean minimal inhibitory concentrations of clindamycin and penicillin against 103 isolates of group A streptococci were 0.033 and 0.007 ,g/ml, respectively. The serum concentrations about 70 min after ingesting 150 mg of clindamycin palmitate averaged 3.8 ,ug/ml and after 250 mg of potassium phenoxymethyl penicillin averaged 0.9 gg/ml. Clindamycin palmitate was as effective as potassium phenoxymethyl penicillin in eradicating group A streptococci from the pharynx in tid and bid regimens. Nevertheless, because of its rash-producing tendency in some patients and higher cost, clindamycin palmitate should not be preferred to penicillin for treatment of streptococcal sore throat in the non-penicillin-allergic patient.
palmitate was as effective as potassium phenoxymethyl penicillin in eradicating group A streptococci from the pharynx in tid and bid regimens. Nevertheless, because of its rash-producing tendency in some patients and higher cost, clindamycin palmitate should not be preferred to penicillin for treatment of streptococcal sore throat in the non-penicillin-allergic patient.
This investigation was initiated as a pilot study in evaluating the efficacy and side effects of two regimens of clindamycin palmitate and two of potassium phenoxymethyl penicillin (K penicillin V) against group A streptococci in upper respiratory illnesses.
Clindamycin palmitate, a new semisynthetic derivative of lincomycin in the form of flavored granules, is a water-soluble ester of clindamycin [7 (S)-chloro-7-deoxylincomycin] and palmitic acid. The palmitate ester is rapidly hydrolyzed to the microbiologically active clindamycin base after ingestion of the granules in a pediatric suspension. The suspension of clindamycin palmitate was introduced in place of clindamycin hydrochloride, which is available in capsule form because of the objectionable taste of the hydrochloride. In vitro antimicrobial activity of clindamycin against group A s.treptococci is approximately the same as that of lincomycin on a weight basis (10, 11, 14) . In mice infe\9eAiih group A streptococci, the oral mean 41twe dose is significantly lower for clindamycin than for lincomycin (9) . In men, oral clindamycin is absorbed two or three times more efficiently than is oral lincomycin, but the average half-life of serum clindamycin activity (2.4 h) after a single usual 150-mg dose is less than the average half-life of serum lincomycin activity (5.2 h) after a single usual 500-mg dose (11, 20) . Oral clindamycin produces less diarrhea than. oral lincomycin after recommended doses (3, 5) .
In one study of group A streptococcal pharyngitis, clindamycin hydrochloride, administered in a dose of about 10 mg per kg per day for 10 days, was more effective than penicillin (15) . In earlier, studies, lincomycin hydrochloride, in a dose of 30 to 40 mg per kg per day for 10 days, was as effective as penicillin in two studies (8, 16) and was more effective than penicillin in two other studies (1, 6 Table 3 ) did not differ significantly in the two regimens and conformed with those in similar studies (1, 19 (19) .
Diplococcus pneumoniae were isolated in pretreatment cultures of three of 94 patients. During therapy of those three patients, the microorganisms were not found in cultures of the two patients on K penicillin V and the one on clindamycin.
Bacterial outcome after primary treatment. Table 2 shows the bacterial failure rates in the clindamycin palmitate and K penicillin V regimens by patient's weight. The difference (15) . Table 3 summarizes the bacterial failure rates for the clindamycin palmitate-and K penicillin V-treated patients by selected variables. They do not differ significantly at the 5% level for the factors evaluated. Even though there was no significant difference between failure rates for clindamycin-and K penicillin V-treated patients according to the presence or absence of homologous streptococci in household contacts after the end of therapy, the failure rates were significantly higher in patients exposed to homologous streptococci than in those not exposed. Thus the high failure rate in K penicillin V-treated 2-to 4-year-olds (5 of 11) could be attributed in two of the five children to exposure to homologous streptococci in household contacts.
A two-tube or greater rise of acute-and convalescant-phase antistreptolysin titers occurred in four of 14 clindamycin-treated patients and in three of 13 K penicillin V-treated patients. Among the seven patients with a twofold or greater ASO rise, the following was noted: the initial titers were low (in five, <60 Todd units; in one, 60 Todd units; and in one, 85 Todd units); antistreptococcal therapy was started early after the onset of illness (in one patient on the first day and in six on the second day); and all follow-up cultures showed no group A streptococci. In this study, clindamycin and K penicillin V equally suppressed ASO responses. Also, in this and in several previous studies (2, 4, 21) , antistreptococcal therapy incompletely prevented a significant ASO response despite complete eradication of group A streptococci and early institution of therapy. There is no relation between the development of ASO and type-specific streptococcal antibody. Table 4 gives the distribution and bacterial failure rates in patients with M-typable and M-nontypable group A streptococci by Mprecipitin types. The failure rates tended to be lower for the M-nontypable streptococci. In the eight patients with failures associated with M-nontypable streptococci, the original and recurrent isolates were the same T-agglutination types, i.e., 28, 2/28, 8 (13) . Pyoderma, however, was detected in only one of the 15 patients harboring those pharyngeal T-typing pattems.
Bacterial outcome after retreatment. Clindamycin palmitate retreatment in seven of nine patients with bacterial failures after K penicillin V resulted in two failures. Potassium penicillin V retreatment in four of five patients with failures after clindamycin palmitate resulted in no failures. The number of patients with bacterial failures retreated with the alternate antibiotic was too small to evaluate.
Failure intervals. Figure 1 shows the intervals in days between the end of primary therapy and bacterial failures in the 14 patients with and without clinical manifestations. In 11 of the 14 patients, pharyngitis or rhinitis was observed at the time of bacterial recurrence. The majority of bacterial failures after both antibiotics were detected during the first week after the end of therapy. Adverse reactions. Possible drug-related rashes developed in eight of 52 patients on clindamycin palmitate. They were first detected in one child on the 3rd day, one on the 7th day, one on the 8th day, three on the 9th day, one on the 10th day, and one on the 11th day after beginning therapy. Of the eight children, six had delayed generalized maculopapular rashes (duration 1 to 7 days), similar to those observed previously by one of the authors in three of 37 children during the second week after beginning a 10-day course of ampicillin (19) and in 11 of 93 children during the second week after beginning a 10-day course of cephaloglycin (17) . One of the children who developed a delayed generalized maculopapular rash on clindamycin had a similar delayed generalized maculopapular rash after a 10-day course of ampicillin for a streptococcal sore throat in 1969. Five of the eight children received the smaller clindamycin dose and four had a history of allergies. The 15% incidence of rashes in this study compares with a reported incidence of delayed maculopapular rashes in 10 of 50 clindamycin hydrochloride-treated patients (5) and an incidence of less than 3% rashes, typically maculopapular, appearing after 5 to 10 days of therapy and clearing despite continuation of therapy in 1,500 clindamycin palmitate-treated children from case reports filed with The Upjohn Co. (3) . The cause of maculopapular rashes occurring during the second week after starting a 10-day drug regimen is unknown (19) . Tests for heterophile antibodies were negative in acute and convalescent sera obtained from four of the eight children with rashes. The incidence of rashes after clindamycin in this study appears to be higher than that reported after lincomycin (1) . No rashes were observed in the K penicillin V-treated patients.
Mild diarrhea developed in two of 52 children on clindamycin and in none on K penicillin V. The lesser frequency of diarrhea after clindamycin in this study than that reported after lincomycin (3, 10) might be attributable to the smaller dose and more rapid absorption of clindamycin.
A rise in the total eosinophile count developed in serial differential blood counts in two of 24 tested children who were on clindamycin and in two of eight tested children who were on K penicillin V.
Of 11 children tested for blood urea nitrogen and serum glutamic pyruvic transaminase at the beginning and end of clindamycin therapy, the only abnormal finding was a slight transient rise of the serum glutamic pyruvic transaminase from 12 to 33 units, falling thereafter to 11 , in one of three tested children who developed rashes referred to above.
Susceptibility tests. The geometric mean minimal inhibitory concentrations of clindamycin and penicillin against 103 group A streptococcal isolates were 0.033 and 0.007 ,ug/ ml, respectively (Table 5) .
Absorption. Figure 2 illustrates the serum concentrations obtained an average of 73 and 70 min, respectively, after ingesting 250 mg of K penicillin V and 150 mg of clindamycin palmitate during therapy. The average serum concentration of clindamycin (3.8 gg/ml) was significantly higher than that of penicillin (0.9 ,g/ml). Those concentrations of clindamycin and penicillin are about 100 times higher than the average minimal inhibitory concentrations of those antibiotics against the group A streptococci shown in Table 5 . Such high ratios suggest that clindamycin and K penicillin V would be effective therapeutically. This was borne out clinically.
No rheumatic fever or acute glomerulonephritis was detected in our patients. 
